Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
BNGO

BNGO - BioNano Genomics Inc Stock Price, Fair Value and News

1.17USD-0.04 (-3.31%)Market Closed
Watchlist

Market Summary

USD1.17-0.04
Market Closed
-3.31%

BNGO Stock Price

View Fullscreen

BNGO RSI Chart

BNGO Valuation

Market Cap

45.4M

Price/Earnings (Trailing)

-0.2

Price/Sales (Trailing)

1.35

EV/EBITDA

-0.05

Price/Free Cashflow

-0.35

BNGO Price/Sales (Trailing)

BNGO Profitability

EBT Margin

-670.56%

Return on Equity

-190.99%

Return on Assets

-124.94%

Free Cashflow Yield

-285.86%

BNGO Fundamentals

BNGO Revenue

Revenue (TTM)

33.6M

Rev. Growth (Yr)

29.04%

Rev. Growth (Qtr)

7.57%

BNGO Earnings

Earnings (TTM)

-227.3M

Earnings Growth (Yr)

-253.88%

Earnings Growth (Qtr)

-189.28%

Breaking Down BNGO Revenue

Last 7 days

1.6%

Last 30 days

-8.1%

Last 90 days

-7.4%

Trailing 12 Months

-92.0%

How does BNGO drawdown profile look like?

BNGO Financial Health

Current Ratio

2.6

BNGO Investor Care

Shares Dilution (1Y)

30.81%

Diluted EPS (TTM)

-6.96

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202329.5M31.5M33.6M0
202220.5M23.3M25.9M27.8M
202110.5M13.2M15.7M18.0M
20209.4M8.4M7.3M8.5M
201912.1M10.9M11.4M10.1M
20189.6M10.7M10.8M12.0M
20170009.5M

Tracking the Latest Insider Buys and Sells of BioNano Genomics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Sep 18, 2023
chaubey alka
acquired
-
-
20,000
chief medical officer
Sep 18, 2023
oldakowski mark
acquired
-
-
20,000
chief operating officer
Jun 13, 2023
mamuszka hannah
bought
49,999
0.76
65,789
-
May 16, 2023
holmlin r. erik
bought
9,639
0.6426
15,000
president and ceo
May 12, 2023
stewart christopher p.
bought
33,415
0.6683
50,000
chief financial officer
May 12, 2023
oldakowski mark
sold (taxes)
-27,387
0.66
-41,496
chief operating officer
May 12, 2023
holmlin r. erik
sold (taxes)
-33,093
0.66
-50,141
president and ceo
Feb 15, 2023
stewart christopher p.
acquired
-
-
105,000
chief financial officer
Feb 15, 2023
chaubey alka
acquired
-
-
120,000
chief medical officer
Feb 15, 2023
oldakowski mark
acquired
-
-
120,000
chief operating officer

1–10 of 29

Which funds bought or sold BNGO recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 16, 2024
GSA CAPITAL PARTNERS LLP
new
-
164,000
164,000
0.01%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
added
186
26,000
60,000
-%
Feb 16, 2024
O'Dell Group, LLC
new
-
16.00
16.00
-%
Feb 15, 2024
JANE STREET GROUP, LLC
new
-
129,737
129,737
-%
Feb 15, 2024
BARCLAYS PLC
new
-
-
-
-%
Feb 14, 2024
TWO SIGMA INVESTMENTS, LP
new
-
770,003
770,003
-%
Feb 14, 2024
MILLENNIUM MANAGEMENT LLC
added
5.48
-193,011
371,260
-%
Feb 14, 2024
VANGUARD GROUP INC
added
26.78
-946,690
3,578,990
-%
Feb 14, 2024
SUSQUEHANNA INTERNATIONAL GROUP, LLP
reduced
-71.13
-361,593
79,406
-%
Feb 14, 2024
TWO SIGMA SECURITIES, LLC
new
-
93,400
93,400
-%

1–10 of 41

Are Funds Buying or Selling BNGO?

Are funds buying BNGO calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own BNGO
No. of Funds

Unveiling BioNano Genomics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
4.88%
1,893,645
SC 13G/A
Jul 07, 2023
blackrock inc.
2.0%
6,136,883
SC 13G/A
Feb 09, 2023
vanguard group inc
5.41%
16,064,444
SC 13G/A
Jan 30, 2023
blackrock inc.
7.8%
23,240,256
SC 13G/A
Feb 09, 2022
vanguard group inc
5.13%
14,825,634
SC 13G
Feb 04, 2022
blackrock inc.
6.5%
18,660,129
SC 13G
Feb 09, 2021
hudson bay capital management lp
1.24%
1,920,000
SC 13G/A
Jan 21, 2021
domain partners viii, l.p.
-
0
SC 13G/A
Feb 14, 2020
sio capital management, llc
4.57%
0
SC 13G/A
Jan 31, 2020
hudson bay capital management lp
7.09%
2,020,000
SC 13G

Recent SEC filings of BioNano Genomics Inc

View All Filings
Date Filed Form Type Document
Feb 13, 2024
SC 13G/A
Major Ownership Report
Jan 08, 2024
8-K
Current Report
Nov 24, 2023
8-K
Current Report

Peers (Alternatives to BioNano Genomics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
205.1B
40.1B
0.08% 5.41%
35.84
5.11
-8.12% -17.45%
70.9B
19.5B
1.90% -2.48%
56.45
3.64
4.02% -22.04%
23.3B
3.8B
13.67% -2.23%
64.31
6.13
-1.48% -28.97%
21.5B
14.9B
3.05% 1.38%
8.08
1.43
2.01% 209.17%
MID-CAP
9.9B
2.7B
6.89% -27.73%
-15.59
3.72
-4.68% 82.43%
9.8B
12.7B
2.56% -12.12%
21.93
0.77
0.68% -30.25%
9.2B
3.5B
8.76% 25.90%
32.49
2.65
4.97% 18.89%
7.0B
3.9B
-8.15% -6.44%
-32
1.78
-2.62% 73.16%
3.4B
342.6M
-1.40% 20.18%
-286.65
10.04
42.19% 84.12%
2.6B
6.6B
-4.32% -4.67%
13.17
0.4
2.61% 0.52%
SMALL-CAP
968.4M
3.1B
8.08% -63.68%
-2.27
0.31
7.95% -543.98%
360.5M
163.3M
8.18% -20.52%
-14.67
2.21
7.14% -56.09%
234.7M
329.5M
3.17% -52.24%
-16.63
0.71
0.49% 64.22%
70.0M
50.3M
4.50% -30.54%
-4.62
1.39
3.23% 20.81%
4.5M
3.7M
-15.66% 215.09%
-0.36
1.19
5.77% 8.23%

BioNano Genomics Inc News

Latest updates
InvestorsObserver14 Feb 202408:10 pm
Yahoo Finance07 Feb 202408:00 am
InvestorsObserver02 Jan 202408:00 am
The Motley Fool6 months ago

BioNano Genomics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue7.6%9,318,0008,662,0007,415,0008,215,0007,221,0006,670,0005,696,0006,302,0004,655,0003,856,0003,168,0003,989,5002,196,0001,182,0001,136,0002,789,1303,313,0002,175,0001,853,0004,013,5372,828,704
Costs and Expenses179.1%115,961,00041,546,00039,913,00039,331,50033,958,00033,550,00030,804,00029,022,00021,832,00017,915,00012,206,00012,305,00010,963,0008,014,00010,042,0008,258,8646,623,0007,464,0006,891,0007,123,9855,729,212
  S&GA Expenses-7.6%24,896,00026,936,00025,976,00025,320,50021,216,00021,783,00020,277,00019,806,50015,327,00013,829,0009,528,0009,428,0008,659,0005,613,0007,368,0005,859,8764,449,0005,056,0004,791,0004,606,6983,224,075
  R&D Expenses-5.6%13,785,00014,610,00013,937,00014,011,00012,742,00011,767,00010,527,0009,215,5006,505,0004,086,0002,678,0002,877,0002,304,0002,401,0002,674,0002,398,8912,174,0002,408,0002,100,0002,517,2872,505,137
EBITDA Margin-49.9%-6.31-4.21-4.30-4.34-4.39-4.48-4.52-4.11-3.65-3.54-3.42-4.31---------
Interest Expenses-4.1%71,00074,00076,00074,50073,00074,00077,00026,0002,000300,000600,0001,068,000589,000561,000761,000731,696578,000645,000273,000266,971404,437
Income Taxes18.2%39,00033,00026,0001,805,50028,00041,0009,000-5,767,00035,0009,0006,000-11,00030,0005,0005,0007,5484,0005,0005,0009,207-2,978
Earnings Before Taxes-189.4%-112,527,000-38,879,000-37,098,000-36,871,500-31,781,000-32,117,000-29,943,000-28,716,000-20,718,000-18,777,000-9,941,000-11,741,000-10,762,000-8,069,000-10,505,000-7,893,022-6,394,000-7,660,000-7,847,000-6,402,249-4,929,075
EBT Margin-46.1%-6.71-4.59-4.67-4.70-4.73-4.78-4.79-4.35-3.90-3.88-3.85-4.83---------
Net Income-189.3%-112,566,000-38,912,000-37,124,000-38,677,000-31,809,000-32,158,000-29,952,000-22,949,000-20,753,000-18,786,000-9,947,000-11,730,000-10,792,000-8,074,000-10,510,000-7,900,000-6,398,000-7,665,000-7,852,000-6,411,457-4,926,097
Net Income Margin-45.4%-6.76-4.65-4.73-4.77-4.51-4.54-4.51-4.03-3.91-3.88-3.85-4.83---------
Free Cashflow28.9%-26,293,000-36,977,000-32,668,000-34,769,000-29,741,000-28,600,000-32,762,000-25,890,000-20,250,000-12,471,000-13,928,000-12,104,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-33.0%18227129230832432234837736035738560.0041.0027.0019.0030.0019.0025.0030.0025.0031.00
  Current Assets-14.7%10512314315721821624227234234237047.0029.0025.0017.0028.0018.0024.0028.0023.0029.00
    Cash Equivalents132.7%35.0015.004.005.0028.0027.0024.0025.0014133336238.0019.0017.008.0017.008.0015.0021.0017.0021.00
  Inventory-100.0%-32.0033.0030.0025.0021.0016.0012.009.005.003.003.005.003.004.003.003.003.001.001.003.00
  Net PPE4.9%21.0020.0019.0018.0016.0014.0013.0010.009.006.006.005.004.003.002.002.001.001.002.002.002.00
  Goodwill-100.0%-77.0077.0077.0056.0056.0056.0056.007.007.007.007.007.00--------
Liabilities11.1%63.0057.0061.0058.0042.0037.0037.0040.0018.0011.0022.0025.0027.0021.0023.0027.0027.0027.0024.0015.0015.00
  Current Liabilities20.0%40.0033.0038.0036.0034.0028.0019.0022.0018.0011.007.009.0025.0020.0023.0026.007.008.005.005.006.00
  Long Term Debt-----------15.0016.002.002.00--19.0019.0018.009.009.00
    LT Debt, Current-------------14.0014.0017.0020.00-----
    LT Debt, Non Current-----------15.0016.002.002.00--19.0019.0018.009.009.00
Shareholder's Equity-44.6%11921523124928228531133734234636335.0015.006.001094.0087.0087.006.0010.0015.00
  Retained Earnings-26.5%-537-424-385-348-310-278-246-216-193-172-153-143-132-121-113-102-94.68-88.28-80.61-72.76-66.35
  Additional Paid-In Capital2.6%65664061859959456555955453551851617914712710910687.0087.0086.0083.0082.00
Shares Outstanding6.3%35.0033.0031.0030.0029.0029.0028.0029.0028.0027.0026.0019.00---------
Float------400---2,045---27.00---27.00---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations28.4%-26,293-36,709-32,400-34,501-29,473-28,332-32,494-25,622-19,982-12,419-13,904-12,104-10,960-7,218-8,032-9,381-7,280-6,316-6,552-4,090-6,099
  Share Based Compensation1.5%3,9923,9323,8825,4796,0595,7775,1024,8022,7881,7583714514473283283563653362891,03353.00
Cashflow From Investing13.0%33,42729,57616,52811,6107,95331,24031,964-92,510-185,60274.00-24.00--2,450---23.06-8.00-30.00--11.83-130
Cashflow From Financing-29.6%12,58817,88114,86214622,6512037.001,96713,766-17,158337,53631,68615,08316,268-1,13518,49121881110,859-32.3119,263

BNGO Income Statement

2023-09-30
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenue:    
Total revenue$ 9,318,000$ 7,221,000$ 25,395,000$ 19,587,000
Operating expenses:    
Total cost of revenue6,569,0005,412,00018,267,00015,447,000
Operating expenses:    
Research and development13,785,00012,742,00042,331,00035,036,000
Selling, general and administrative24,896,00021,216,00077,809,00063,275,000
Goodwill impairment77,280,000077,280,0000
Total operating expenses115,961,00033,958,000197,420,00098,311,000
Loss from operations(113,212,000)(32,149,000)(190,292,000)(94,171,000)
Other income (expense):    
Interest income730,000436,0002,122,000737,000
Interest expense(71,000)(73,000)(221,000)(223,000)
Other income (expense)26,0005,000(113,000)(183,000)
Total other income (expense)685,000368,0001,788,000331,000
Loss before income taxes(112,527,000)(31,781,000)(188,504,000)(93,840,000)
Benefit (provision) for income taxes(39,000)(28,000)(98,000)(79,000)
Net loss$ (112,566,000)$ (31,809,000)$ (188,602,000)$ (93,919,000)
Net loss per share, basic (in dollars per share)$ (3.22)$ (1.10)$ (5.85)$ (3.28)
Net loss per share, diluted (in dollars per share)$ (3.22)$ (1.10)$ (5.85)$ (3.28)
Weighted-average common shares outstanding, basic (in shares)35,00128,97032,24628,663
Weighted-average common shares outstanding, diluted (in shares)35,00128,97032,24628,663
Product revenue    
Revenue:    
Total revenue$ 6,456,000$ 5,253,000$ 18,512,000$ 14,254,000
Operating expenses:    
Total cost of revenue5,105,0003,708,00013,714,00011,257,000
Service and other revenue    
Revenue:    
Total revenue2,862,0001,968,0006,883,0005,333,000
Operating expenses:    
Total cost of revenue$ 1,464,000$ 1,704,000$ 4,553,000$ 4,190,000

BNGO Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 34,568$ 5,091
Investments29,014108,095
Accounts receivable, net8,6697,022
Inventories current26,42929,761
Prepaid expenses and other current assets5,8577,329
Total current assets104,537157,298
Restricted cash400400
Property and equipment, net21,26618,029
Operating lease right-of-use assets6,1707,222
Finance lease right-of-use assets3,5553,707
Intangible assets, net35,76641,143
Goodwill077,289
Other long-term assets10,2102,414
Total assets181,904307,502
Current liabilities:  
Accounts payable15,36912,534
Accrued expenses11,55210,552
Contract liabilities811871
Operating lease liability2,1862,260
Finance lease liability276285
Contingent consideration10,0009,382
Total current liabilities40,19435,884
Operating lease liability, net of current portion4,0855,504
Finance lease liability, net of current portion3,5953,619
Contingent consideration, net of current portion14,88012,970
Long-term contract liabilities151127
Total liabilities62,90558,104
Commitments and contingencies (Note 7)
Stockholders’ equity:  
Preferred stock, $0.0001 par value; 10,000,000 shares authorized at September 30, 2023 and December 31, 2022; no shares issued and outstanding at September 30, 2023 and December 31, 202200
Common stock, $0.0001 par value, 400,000,000 shares authorized at September 30, 2023 and December 31, 2022; 35,349,000 and 29,718,000 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively33
Additional paid-in capital656,406599,234
Accumulated deficit(537,317)(348,715)
Accumulated other comprehensive loss(93)(1,124)
Total stockholders’ equity118,999249,398
Total liabilities and stockholders’ equity$ 181,904$ 307,502
BNGO
Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.
 CEO
 WEBSITEbionano.com
 EMPLOYEES405

BioNano Genomics Inc Frequently Asked Questions


What is the ticker symbol for BioNano Genomics Inc? What does BNGO stand for in stocks?

BNGO is the stock ticker symbol of BioNano Genomics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of BioNano Genomics Inc (BNGO)?

As of Wed Feb 21 2024, market cap of BioNano Genomics Inc is 45.44 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BNGO stock?

You can check BNGO's fair value in chart for subscribers.

What is the fair value of BNGO stock?

You can check BNGO's fair value in chart for subscribers. The fair value of BioNano Genomics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of BioNano Genomics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BNGO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is BioNano Genomics Inc a good stock to buy?

The fair value guage provides a quick view whether BNGO is over valued or under valued. Whether BioNano Genomics Inc is cheap or expensive depends on the assumptions which impact BioNano Genomics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BNGO.

What is BioNano Genomics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Feb 21 2024, BNGO's PE ratio (Price to Earnings) is -0.2 and Price to Sales (PS) ratio is 1.35. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BNGO PE ratio will change depending on the future growth rate expectations of investors.